| Name | Title | Contact Details |
|---|
UT Medical Group is the private practice arm of the University of Tennessee Health Science Center (UTHSC) faculty. Because the physicians in our group are actively involved in teaching and research, they remain current with the latest medical developments. As a not-for-profit, non-tax-supported group practice, UT Medical Group is dedicated to quality patient care, medical education, and medical research. This allows us to offer many unique, advanced health care services to people in the Mid-South at competitive prices. Ties to UTHSC allow the physicians at UT Medical Group access to the latest treatments, special protocols and labs, as well as a broad spectrum of professionals with advanced degrees in nursing, nutrition, pharmacology, psychology, and more. This involvement benefits not only our patients' treatments, but keeps the physicians at the top of their fields.
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries.
Ameriplan is a Foley, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our mission is to change people’s lives by reducing pain and offering services and support to enhance wellness, vitality and prosperity. Radiant Health Management owns and runs progressive, profitable treatment centers that offer cutting-edge therapies and services that improve people’s lives by reducing pain and restoring hope and function. Our Radiant Pain Relief Centres offer a highly refined and patient centered care model, built around an exclusive FDA-cleared pain treatment technology that create significant and lasting pain relief without drugs, needles or surgery.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.